ReviewClinica chimica acta; international journal of clinical chemistry2022
Miniaturized Real-Time PCR systems for SARS-CoV-2 detection at the Point-of-Care.
Review in Clinica chimica acta; international journal of clinical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Beads-on-a-Tip testing for ultrasensitive antigen detection across a large dynamic range.Smart molecules : open access · 2026Article
- Simultaneous Detection and Differentiation of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Viruses in Respiratory Specimens Using the VitaSIRODiagnostics (Basel, Switzerland) · 2025Article
- Next-Generation Nucleic Acid-Based Diagnostics for Viral Pathogens: Lessons Learned from the SARS-CoV-2 Pandemic.Microorganisms · 2025Review
- Lyophilised Reverse Transcriptase and Polymerase for Point-of-Care Diagnostics of SARS-CoV-2.Microbial biotechnology · 2025Article
- Integrated and streamlined microfluidic device for molecular diagnosis of pathogen through direct PCR amplification.Heliyon · 2025Article
- Article
- A Microfluidic-Based Sensing Platform for Rapid Quality Control on Target Cells from Bioreactors.Sensors (Basel, Switzerland) · 2024Article
- Evaluating the efficiency of ELISA, monoplex and multiplex probe-based real-time reverse-transcription PCR assays in the detection of SARS-CoV-2 (COVID-19) and influenza A and B viruses: A cross-sectional study.Health science reports · 2024Article
- Advances in Nucleic Acid Assays for Infectious Disease: The Role of Microfluidic Technology.Molecules (Basel, Switzerland) · 2024Review
- MassARRAY: a high-throughput solution for rapid detection of foodborne pathogens in real-world settings.Frontiers in microbiology · 2024Article
- Article
- Ultrasensitive qPCR platform for rapid detection of bacterial contamination of raw biological samples at the point of care.Heliyon · 2023Article
- Strategies for the Voltammetric Detection of Loop-Mediated Isothermal Amplification.Micromachines · 2023Review
- Smart Nanostructured Materials for SARS-CoV-2 and Variants Prevention, Biosensing and Vaccination.Biosensors · 2022Review
- Principles and Applications of Loop-Mediated Isothermal Amplification to Point-of-Care Tests.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two years, SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2) infection has spread globally causing multi-organ disease and severely impacting the healthcare systems of all countries. Accordingly, the development of easy-to-access diagnostic devices has become essential to limit the effect of the virus worldwide. Real-Time PCR is considered the gold standard to identify SARS-CoV-2 infection due to high sensitivity, affordability, and capacity to detect low viral loads at early disease stage. Advances in lab on a chip technology has led to the development of some Point-of-Care (POC) devices using Real-Time PCR and approved by the United States Food and Drug Administration. We provide an overview on recently developed POC tests for the rapid diagnosis of COVID-19 infection. Practical applications of miniaturized devices based on viral genome amplification as well as favorable features such as reduced sample processing time, ease of use by non-specialized personnel, and the potential of PCR-based POC technologies will be highlighted and reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.